Drug Profile
Onabotulinum toxin A - AbbVie
Alternative Names: BoNTA; Botox; Botulinum toxin A injectable-AbbVie; GSK 1358820; OnabotA X; OnabotulinumtoxinA X; Vistabel; VistabexLatest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie; Allergan; GlaxoSmithKline; GSK; Johns Hopkins University; Queens University; Temple University; University of Illinois at Chicago; Wake Forest University School of Medicine
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Blepharospasm; Dysphonia; Facial wrinkles; Glabellar lines; Hyperhidrosis; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
- Registered Equinus foot deformity
- Preregistration Hypertrophy
- Phase III Muscle pain; Raynaud's disease
- Phase II Carpal tunnel syndrome; Essential tremor; Gastrointestinal disorders; Herpes labialis; Interstitial cystitis; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Pain; Premature ejaculation
- Phase I/II Pruritus
- No development reported Benign prostatic hyperplasia; Constipation; Prostatitis
- Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome
Most Recent Events
- 16 Feb 2024 Preregistration for Hypertrophy in China (IM), before February 2024 (AbbVie pipeline, February 2024)
- 18 Dec 2023 AbbVie plans a phase III trial for Glabellar lines in China (IM, Injection) in December 2023 (NCT06174688)
- 12 Dec 2023 AbbVie initiates a phase III trial for Glabellar lines in China (IM, Injection) (NCT06174688)